Freeline Therapeutics Holdings plc Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Freeline Therapeutics Holdings plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2020 to Q1 2023.
  • Freeline Therapeutics Holdings plc Share-based Payment Arrangement, Expense for the quarter ending March 31, 2023 was $973K, a 29.3% decline year-over-year.
  • Freeline Therapeutics Holdings plc annual Share-based Payment Arrangement, Expense for 2022 was $5.08M, a 52.7% decline from 2021.
  • Freeline Therapeutics Holdings plc annual Share-based Payment Arrangement, Expense for 2021 was $10.7M, a 72.8% increase from 2020.
  • Freeline Therapeutics Holdings plc annual Share-based Payment Arrangement, Expense for 2020 was $6.2M, a 325% increase from 2019.
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $973K -$403K -29.3% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q1 2022 $1.38M -$1.17M -46% Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 $2.55M +$2.22M +672% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-10
Q1 2020 $330K Jan 1, 2020 Mar 31, 2020 6-K 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.